Pegfilgrastim: evidence in support of its use with cytotoxic chemotherapy.

Abstract

The advent of granulocyte colony-stimulating factor, in particular filgrastim, in clinical use more than 10 years ago made a significant impact on the management of neutropenia and its complications. More recently, the application of pegylation technology has created a second-generation molecule, pegfilgrastim, with significantly altered pharmacokinetic… (More)

Topics

Cite this paper

@article{Ng2005PegfilgrastimEI, title={Pegfilgrastim: evidence in support of its use with cytotoxic chemotherapy.}, author={Raymond Ng and Michael D. Green}, journal={Expert review of anticancer therapy}, year={2005}, volume={5 4}, pages={585-90} }